[Acyclovir in the treatment of varicella in immunocompetent children].

S Catania, C Ajassa, M S Magno, G Berardelli, R Bellagamba, S Tzantzoglou, M Falciano, C M Lanzalone, N Catania
{"title":"[Acyclovir in the treatment of varicella in immunocompetent children].","authors":"S Catania,&nbsp;C Ajassa,&nbsp;M S Magno,&nbsp;G Berardelli,&nbsp;R Bellagamba,&nbsp;S Tzantzoglou,&nbsp;M Falciano,&nbsp;C M Lanzalone,&nbsp;N Catania","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We evaluated safety and tolerance of acyclovir ACV per os in immunocompetent children affected by chicken-pox admitted to our department from January 1993 to December 1994. 183 subjects (102 males and 81 females) aged between 0 and 14 years were treated by ACV (80 mg/kg/daily in 4 divided doses): 88 children were treated within 24 hours and 95 subjects within 48 hours from the onset of symptoms. The control group consisted of 83 children (52 males and 31 females) aged between 0 to 14 years. In all patients routine blood-test were performed and in those with respiratory illness Chest-Rx was also done. We evaluated clinical course, degree of eruption, the appearance and kind of complications, duration of hospitalization, the compliance and the potential consequences on specific antibody response. Our results show a faster improvement of clinical symptoms in treated patients with respect to the control group with shortening of the period of the fever, itch and appearance of new vescicles. The percentage of complications was lower in treated than in untreated patients. 16 cases tested for specific antibody response showed protective titers six months after treatment. In conclusion, ACV administered per os within 48 hours from onset of exanthema causes reduction of the period and the degree of general symptoms and exanthema, a lower incidence of complications even if non statistically significant. The drug is safe and well-tolerated.</p>","PeriodicalId":21382,"journal":{"name":"Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques","volume":"17 4","pages":"115-23"},"PeriodicalIF":0.0000,"publicationDate":"1995-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We evaluated safety and tolerance of acyclovir ACV per os in immunocompetent children affected by chicken-pox admitted to our department from January 1993 to December 1994. 183 subjects (102 males and 81 females) aged between 0 and 14 years were treated by ACV (80 mg/kg/daily in 4 divided doses): 88 children were treated within 24 hours and 95 subjects within 48 hours from the onset of symptoms. The control group consisted of 83 children (52 males and 31 females) aged between 0 to 14 years. In all patients routine blood-test were performed and in those with respiratory illness Chest-Rx was also done. We evaluated clinical course, degree of eruption, the appearance and kind of complications, duration of hospitalization, the compliance and the potential consequences on specific antibody response. Our results show a faster improvement of clinical symptoms in treated patients with respect to the control group with shortening of the period of the fever, itch and appearance of new vescicles. The percentage of complications was lower in treated than in untreated patients. 16 cases tested for specific antibody response showed protective titers six months after treatment. In conclusion, ACV administered per os within 48 hours from onset of exanthema causes reduction of the period and the degree of general symptoms and exanthema, a lower incidence of complications even if non statistically significant. The drug is safe and well-tolerated.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[无环鸟苷治疗免疫功能正常儿童水痘]。
我们对1993年1月至1994年12月在我科就诊的免疫功能正常的水痘患儿进行无环鸟苷ACV的安全性和耐受性评价。年龄在0 - 14岁之间的183名受试者(102名男性,81名女性)接受ACV治疗(80mg /kg/日,分4次给药):88名儿童在症状出现后24小时内接受治疗,95名受试者在48小时内接受治疗。对照组83例,男52例,女31例,年龄0 ~ 14岁。所有患者都进行了常规血液检查,呼吸道疾病患者也进行了胸部x光检查。我们评估了临床病程、出疹程度、并发症的出现和种类、住院时间、依从性和对特异性抗体反应的潜在影响。我们的结果显示,与对照组相比,治疗组患者的临床症状改善更快,发热、瘙痒和新囊泡出现的时间缩短。治疗组的并发症发生率低于未治疗组。治疗6个月后,16例特异性抗体反应检测显示出保护效价。综上所述,即使无统计学意义,在发病后48小时内给予患者ACV可减少一般症状和痛风的持续时间和程度,降低并发症的发生率。这种药物安全且耐受性良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The mouth-stomach crossing of Helicobacter pylori. HCV and dermatomyositis: report of 5 cases of dermatomyositis in patients with HCV infection. Effective treatment of osteoarthritis with a 150 mg prolonged-release of diclofenac sodium. Toxoplasmosis in pregnancy: research on 2295 women in Rome and its province. Transcranial Doppler validation of hemodynamic vertebrobasilar insufficiency diagnosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1